MANGOCEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 19, 2026
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $174,562 | $1,486,338 |
| Prepaid expenses | 897 | 7,021 |
| Prepaid expenses - related party | - | 120 |
| Deposits | 16,957 | 33,899 |
| Due from related party | 20,056 | 20,056 |
| TOTAL CURRENT ASSETS | 212,472 | 1,547,434 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $3,518 and $3,268 | 1,544 | 1,794 |
| Operating lease right-of-use assets | 294,061 | 307,861 |
| Intangible assets - acquired patents and license, net of amortization | 13,941,146 | 14,232,484 |
| TOTAL NON-CURRENT ASSETS | 14,236,751 | 14,542,139 |
| TOTAL ASSETS | $14,449,223 | $16,089,573 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 529,800 | 416,682 |
| Payroll tax liabilities | 3,297 | 9,421 |
| Operating lease liability, current | 57,058 | 307,823 |
| Other liabilities - patent purchase payable | 147,451 | 156,642 |
| TOTAL CURRENT LIABILITIES | 737,606 | 890,568 |
| LONG-TERM LIABILITIES | ||
| Operating lease liability, net of current portion | 236,965 | - |
| TOTAL LONG-TERM LIABILITIES | 236,965 | - |
| TOTAL LIABILITIES | 974,571 | 890,568 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 10) | - | |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 50 and 50 shares were issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | - | - |
| Series C Convertible Preferred stock, (par value $0.0001), 6,250,000 shares authorized, 980,000 and 980,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 98 | 98 |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 16,967,421 and 15,888,795 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1,698 | 1,589 |
| Stock warrants | 324,288 | 324,288 |
| Additional paid in capital | 57,203,924 | 55,524,812 |
| Accumulated deficit | (44,050,630) | (40,647,480) |
| Accumulated other comprehensive loss | (3,193) | (2,760) |
| TOTAL MANGOCEUTICALS, INC. STOCKHOLDERS’ EQUITY | 13,476,185 | 15,200,547 |
| Non-controlling interest | (1,533) | (1,542) |
| TOTAL STOCKHOLDERS’ EQUITY | 13,474,652 | 15,199,005 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $14,449,223 | $16,089,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.